4//SEC Filing
Altarac David 4
Accession 0001104659-22-023770
CIK 0001724344other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:01 PM ET
Size
8.4 KB
Accession
0001104659-22-023770
Insider Transaction Report
Form 4
Altarac David
Chief Medical Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2021-07-16+92.307→ 92,307 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (92,307 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−120,000→ 0 totalExercise: $5.70Exp: 2029-11-03→ Common Stock (120,000 underlying)
Footnotes (3)
- [F1]The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on November 4, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F2]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 120,000 shares of issuer's common stock granted to the Reporting Person on November 4, 2019. In exchange, the Reporting Person received a replacement option for 92,307 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F3]Sixty-seven percent (67%) of this award will vest on July 16, 2022, and one-sixteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
Documents
Issuer
Entasis Therapeutics Holdings Inc.
CIK 0001724344
Entity typeother
Related Parties
1- filerCIK 0001792615
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:01 PM ET
- Size
- 8.4 KB